Table 2 Changes in the serum markers at baseline and postintervention
Serum Levels of Markers | Aspirin group | Placebo group | Aspirin vs. placebo | ||||||
|---|---|---|---|---|---|---|---|---|---|
Baseline | At the end of the intervention period | p-value* | Baseline | At the end of the intervention period | p-value* | At the end of the intervention period Aspirin | At the end of the intervention period Placebo | p-value** | |
Estradiol (pg/mL) Median (IQR) | 15.00 (12.00–20.90) | 12.70 (8.50–16.60) | 0.01* | 15.00 (11.35–22.25) | 16.50 (11.30–22.10) | 0.12 | 12.70 (8.50–16.60) | 16.50 (11.30–22.10) | <  0.01 |
Testosterone (ng/dL) Median (IQR) | 0.50 (0.40–0.80) | 0.50 (0.40–0.70) | 0.51 | 0.40 (0.40–0.60) | 0.40 (0.40–0.60) | 0.10 | 0.50 (0.40–0.70) | 0.40 (0.40–0.60) | 0.58 |
SHBG (nmol/L) Median (IQR) | 26.30 (17.50–36.00) | 26.00 (19.70–33.70) | 0.80 | 26.30 (14.32–33.50) | 25.20 (13.42–28.27) | 0.08 | 26.00 (19.70–33.70) | 25.20 (13.42–28.27) | 0.33 |